Global Next-Generation Cancer Diagnostics Market 2022-2028
Cancer ranks as a leading cause of death and an important barrier to increasing life expectancy in every country of the world. Cancer's rising prominence as a leading cause of death partly reflects marked declines in mortality rates of stroke and coronary heart disease, relative to cancer, in many countries. Next-generation cancer diagnostics aim to promote prevention and early detection of cancer. Garnering a CAGR of 18.9% from 2022 to 2028, the global next-generation cancer diagnostics market is projected to reach worth of USD 19,777 million by 2028-end, according to a new report by Gen Consulting Company.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global next-generation cancer diagnostics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the next-generation cancer diagnostics industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the technology, and region. The global market for next-generation cancer diagnostics can be segmented by technology: polymerase chain reaction (PCR), next-generation sequencing (NGS), others. The PCR segment held the largest share of the global next-generation cancer diagnostics market in 2021 and is anticipated to hold its share during the forecast period. Next-generation cancer diagnostics market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW).
By technology:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook